In 2011, the drug tafamidis, a compound with high ability to bind and stabilize the tetrameric fold of TTR, was approved by the European Medical Agency for treatment of TTR-related hereditary amyloidosis patients with stage I polyneuropathy [15]. This evidence concerns the gene TTR and polyneuropathy.